Latest from Sidney Kimmel Cancer Center at Jefferson

Leonard G. Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the prevalence of genetic testing in prostate cancer.

Leonard G. Gomella, MD, underscores the need for genetic testing in prostate cancer, sheds light on important biomarkers in the space, and explains how these tests are helping oncologists facilitate a precision medicine approach.

The Sidney Kimmel Cancer Center – Jefferson Health recently welcomed Anjali Mishra, PhD, and Nitin Chakravarti, PhD, to a growing team of researchers focused on hematologic cancers.

For women at average risk for breast cancer who are between the ages of 40 and 49 years, clinicians should have a personalized approach on whether their patients should be screened with mammography prior to the age of 50.

Higher survival rates were observed with radical prostatectomy and adjuvant radiotherapy compared with radiotherapy and androgen deprivation therapy in men with locally advanced prostate cancer.

The Sidney Kimmel Cancer Center – Jefferson Health announces a collaboration with Driver, a first-of-its-kind global technology platform that connects cancer patients to the best treatments, which launched today in the United States and China.

Benjamin P. Levy, MD, highlights the pros and cons of the different platforms for circulating tumor DNA detection, as well as the benefits and limitations of liquid biopsies.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.